Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Nov 27, 2017 6:46am
448 Views
Post# 27035714

RE:RE:RE:seeking Alpha

RE:RE:RE:seeking Alpha

Yes this looks encouraging but the report acknowledges that dates listed are projections. Let's hope it happens. A december BLA approval is possible provided the plant inspection purportedly undertaken last week is favourable. Perhaps there will be a PR on the outcome of the inspection this week or next??

2017 Fall Pipeline Update

Oklahoma Health Care Authority

November 2017

Introduction

The following report is a pipeline review compiled by the University of Oklahoma College of

Pharmacy. Information in this report is focused on medications not yet approved by the U.S.

Food and Drug Administration (FDA). The pipeline report is not an all-inclusive list, and

medications expected to be highly utilized or have a particular impact in the SoonerCare

population have been included for review. Pipeline data is collected from a variety of sources

and is subject to change; dates listed are projections and all data presented are for

informational purposes only. Costs listed in the following report do not reflect rebated prices or

net costs. For Ryplazim the anticipated FDA response date is 12/2017.

Bullboard Posts